CDT enters evaluation agreement with Manoira for AZD1656 and AZD5904

Evaluation agreement: Manoira will evaluate AZD1656 and AZD5904 in animal health applications combined with its products to determine whether the assets improve efficacy, safety, formulation or other commercially relevant characteristics.

Fee consideration: CDT settled the US$195,000 evaluation fee with 1,347,616 shares of common stock at $0.1447 per share; the agreement states the fee is payable in full on receipt of a valid invoice.

Evaluation timeline: The parties must agree the Evaluation Programme in writing no later than November 30, 2026, Manoira must deliver written results within 60 days of completion, and the agreement continues for six months from the October 22, 2026 effective date unless terminated or extended in writing.

Potential commercialization: If the results show an improved product offering, the parties must negotiate in good faith for 120 days after delivery of results; neither party is obliged to enter a commercial agreement, which would bind only upon a separate signed writing.

Intellectual property: Evaluation IP relating solely to the CDT assets belongs to CDT, IP relating solely to the Manoira products belongs to Manoira, and IP relating to the combination is jointly owned and may not be commercially exploited except under a commercial agreement.

Product launch context: Manoira is preparing to launch its first range of animal health products in the first quarter of 2027 and is currently in the manufacturing and testing phase.

Unregistered share issuances: Besides the Manoira shares, CDT issued 437,779 Sarborg shares under an August 31, 2026 securities purchase agreement, 397,374 service-provider shares for consulting services, and 499,616 shares to Dr. Regan in lieu of $65,000 of severance.